LANXESS successfully places EUR 500 million benchmark bond

Cologne

The specialty chemicals company LANXESS has successfully placed a 6-year-tenor euro benchmark bond with a coupon of 0.0 percent in the European capital market. LANXESS will use the funds to finance the planned acquisition of the microbial control business of US-based chemical company IFF.

The new bond is listed on the Luxembourg Stock Exchange in denominations of EUR 1,000.

“We have secured a first step of financing already quickly after the announcement of the acquisition of IFF Microbial Control and are happy about the very receptive reaction of the capital market to our offering,” said LANXESS Chief Financial Officer Michael Pontzen.

LANXESS' issuer ratings are currently Baa2 (Moody’s), BBB (Standard & Poor’s) and BBB+ (Scope). A bank consortium of active joint bookrunners comprising Citi, Société Générale and Unicredit was mandated to place the bond.

Information for editors:
All LANXESS news releases and their accompanying photos can be found at http://press.lanxess.com. Recent photos of the Board of Management and other LANXESS image material are available at http://photos.lanxess.com.

You can find further information concerning LANXESS chemistry at http://lanxess.com/en/Media/Stories.

MORE ABOUT THIS TOPIC

PRESS RELEASE
PIR insulation panel, aluminium-laminated

LANXESS sharpens flame-retardant portfolio for rigid PU and PIR insulation

September 22, 2026
PRESS RELEASE
Funny portrait of a welsh corgi pembroke dog showering with shampoo.  Dog taking a bubble bath in grooming salon.

LANXESS at the SEPAWA Congress 2026

September 22, 2026
PRESS RELEASE
Vulkanox 4060

Sustainable Tire Protection: LANXESS Launches New Anti-Aging Agent as an Alternative for 6PPD

September 08, 2026
PRESS RELEASE
LANXESS manufactures an extensive product portfolio of lubricants. It includes additives and additive systems, synthetic base fluids and ready-to-use lubricants. 

LANXESS and KRAHN Chemie to Showcase Metal Working Fluid Solutions at Lubricant Expo Europe 2026

September 08, 2026
PRESS RELEASE
Woman working in Laboratory Kromm DL14

Saltigo showcases its phosgenation expertise and peptide synthesis reagents at CPHI Milan

September 07, 2026